Answers are grounded in this paper and cite their sources.
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a genetically heterogeneous disease associated with sudden cardiac death (SCD). Risk stratification is challenging in genotype-positive individuals with borderline phenotypic expression. CASE SUMMARY: A 54-year-old man was referred for SCD risk stratification in familial HCM. His daughter had obstructive HCM, underwent septal myomectomy, and received an implantable cardioverter-defibrillator after a cardiac arrest. The patient was asymptomatic with mild septal hypertrophy and nonsustained ventricular tachycardia. Genetic testing revealed 2 pathogenic MYH7 variants in his daughter (Ala655Thr and Gly571Arg); the patient carried only Ala655Thr, whereas his wife carried Gly571Arg. Repeat cardiac magnetic resonance imaging (MRI) under anesthesia revealed late gadolinium enhancement burden of 23%, prompting implantable cardioverter-defibrillator insertion. DISCUSSION: This case underscores the value of cardiac MRI and genetic testing in individualizing SCD risk assessment when conventional HCM markers are insufficient. TAKE-HOME MESSAGES: Genotype-phenotype discordance in familial HCM underscores the need for family-based genetic evaluation and individualized risk stratification. Cardiac MRI is invaluable for SCD risk assessment in ambiguous cases.
No takes yet. Share an insight, caveat, or question.
Hammad et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: